论文部分内容阅读
目的评价重组人干扰素α1b治疗小儿疱疹性咽峡炎的有效性及安全性。方法以2012年6月至2012年8月本溪市中心医院儿科病房102例确诊为疱疹性咽峡炎的患儿为研究对象,随机分为观察组52例,对照组50例。所有患儿给予维素C、水溶性维生素支持治疗的基础上,观察组给予重组人干扰素α1b治疗,对照组给予炎琥宁治疗,均以5d为限,观察治疗期间患儿的临床症状及体征改变,并记录药物不良反应。结果观察组52例中,显效45例,有效5例,总有效率为96.2%,1例出现轻度不良反应,停药2d后恢复正常。对照组50例,显效38例,有效8例,总有效率92.0%,5例出现消化道不良反应,停药并对症治疗2d后恢复正常。结论重组人干扰素α1b治疗小儿疱疹性咽峡炎,短期内疗效显著,未见严重不良反应。
Objective To evaluate the effectiveness and safety of recombinant human interferon α1b in the treatment of herpes angina in children. Methods From June 2012 to August 2012, 102 pediatric patients diagnosed as herpetic angina in the pediatric ward of Benxi Central Hospital were randomly divided into observation group (n = 52) and control group (n = 50). All children given vitamin C, water-soluble vitamins based on the supportive treatment, the observation group given recombinant human interferon alpha 1b treatment, the control group was treated with Yan Hu Ning, were 5d for the treatment of children during the observation of clinical symptoms and Signs changes, and record adverse drug reactions. Results In the observation group of 52 cases, 45 cases were markedly effective and 5 cases were effective. The total effective rate was 96.2%. One case had mild adverse reactions and returned to normal after 2 days of withdrawal. The control group of 50 cases, 38 cases markedly effective in 8 cases, the total effective rate was 92.0%, 5 cases of gastrointestinal adverse reactions, withdrawal and symptomatic treatment after 2d returned to normal. Conclusion Recombinant human interferon α1b treatment of children with herpes angina, the short term effect was significant, no serious adverse reactions.